key: cord-0847689-dnsan8s8
authors: Williams, Richard K.; Raimondo, John; Cahn, David; Williams, Aldon; Schell, Daniel
title: Clarification: Whole‐organ transdermal photobiomodulation (PBM) of COVID‐19: A 50‐patient case study
date: 2022-01-24
journal: J Biophotonics
DOI: 10.1002/jbio.202190015
sha: abf2cd24583bee052fc473acc2c1d187657dd56a
doc_id: 847689
cord_uid: dnsan8s8

nan

A reader of this research article [1] raised concerns about the accuracy of the Conflict of Interest statement.

The authors of this article assert that there was no intent to violate any ethical guidelines or intentionally avoid full disclosure of all conflicts of interest. This clarification discloses in more detail the positions that the authors hold in their respective companies and their relationships to each other.

Richard K. Williams is founder, CEO, president, CTO, and a shareholder of Applied BioPhotonics, Ltd. (ABP) and cofounder and CEO of LightMD, Inc., a member of the ABP group of global affiliates. He is also founder, CEO, and CTO of technology-innovator Adventive Technology Ltd., and a founding member of HyperSphere.ai and several blockchain DAOs. ABP is a GMP-certified device manufacturer, system specifier, and IP holder of medical devices and PBM therapy products. Daniel Schell is co-founder and president of LightMD, Inc. and a minority shareholder of ABP. Mr. Schell is not an employee of ABP. LightMD, Inc. is a US FDA-registered, licensed importer and distributor of ABP products in the United States. Dr. John Raimondo, Dr. David Cahn, and Dr. Aldon Williams are independently operating licensed physicians and not service providers for either company. They are not shareholders, employees or paid consultants of either LightMD or ABP and received no compensation for their involvement in performing this study. Any other doctors who assisted in this study also received no compensation. No patients were paid or charged for receiving PBM therapy in this study. No patients requesting therapy were turned away from receiving treatments.

e202190015. www.biophotonics-journal.org © 2022 Wiley-VCH GmbH